Rvp-001
Brain Neoplasms, Benign
Reveal Pharmaceuticals Inc.Phase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Brain Neoplasms, Benign cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
5-ala Constantinos Hadjipanayis | Phase 2 | CCC |
Pioglitazone Wake Forest University Health Sciences | Phase 1 | CC |
Same molecule, other indications
Rvp-001 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →